{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"0.8","upperLimit":"90.6","value":"33.3"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"}],"units":"Participants"}],"description":"ORR: percentage of participants with sCR, CR, VGPR or PR. For hematologic tumors (multiple myeloma), sCR: negative immunofixation on the serum, urine, disappearance of any soft tissue plasmacytomas and \\<5% plasma cells in bone marrow plus normal FLC ratio and absence of clonal cells in bone marrow by immunohistochemistry or immunofluorescence; CR: CR: negative immunofixation on the serum, urine, disappearance of any soft tissue, plasmacytomas and \\<5% plasma cells in bone marrow; VGPR: serum and urine M-component detectable by immunofixation but not on electrophoresis or greater than equal to \\>=90% reduction in serum M-component plus urine M-component \\<100 mg per 24hour (hr); PR: \\>50% reduction of serum M-protein and reduction in 24 hr urinary M-protein by \\>90% or to \\<200 mg/24 hr.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received an oral dose of 45 mg of binimetinib tablets (3 tablets of 15 mg) twice daily in each cycle starting from Cycle 1 Day 1 (1 cycle =28 days) until disease progression, unacceptable toxicity, death, or discontinuation from the study treatment due to any other reason. Maximum treatment exposure was approximately of 19.4 months.","id":"OG000","title":"Binimetinib (MEK162)"}],"paramType":"NUMBER","populationDescription":"Full analysis set included all the participants who had received at least 1 dose of study drug. Here, \"Overall Number of Participants Analyzed\" signifies participants evaluable for this outcome measure.","reportingStatus":"POSTED","timeFrame":"From the start of the treatment until disease progression (maximum up to 19.4 months)","title":"ORR for Hematologic Tumors: Multiple Myeloma","type":"SECONDARY","unitOfMeasure":"Percentage of participants"}